Ainos (NASDAQ:AIMD) Posts Earnings Results

Ainos (NASDAQ:AIMD) issued its quarterly earnings data on Wednesday. The company reported ($0.41) earnings per share (EPS) for the quarter, Zacks reports. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 140.10%.

Ainos Price Performance

Shares of NASDAQ:AIMD traded up $0.03 during midday trading on Wednesday, reaching $1.71. The company’s stock had a trading volume of 31,526 shares, compared to its average volume of 19,837. The business’s fifty day simple moving average is $1.59 and its 200-day simple moving average is $1.94. The company has a debt-to-equity ratio of 1.45, a current ratio of 1.06 and a quick ratio of 0.78. Ainos has a fifty-two week low of $1.26 and a fifty-two week high of $4.50. The company has a market capitalization of $12.43 million, a P/E ratio of -0.48 and a beta of 2.29.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. DRW Securities LLC raised its holdings in shares of Ainos by 272.6% in the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after buying an additional 48,439 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Ainos by 13.1% in the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after buying an additional 7,700 shares during the last quarter. Two Sigma Investments LP bought a new position in shares of Ainos in the third quarter valued at about $80,000. Finally, Mariner LLC bought a new position in shares of Ainos in the fourth quarter valued at about $37,000.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ainos in a report on Friday, May 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Ainos presently has a consensus rating of “Sell”.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical?stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI?401, is an inhaled formulation of ibuprofen in a dry powder format.